535. Comparison of Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Monoclonal Antibody Therapy (MAT) with Bamlamivimab or Casirivimab-Imdevimab

BACKGROUND: Limited options currently exist for treatment of patients diagnosed with symptomatic coronavirus 2019 (COVID-19). Monoclonal antibody therapy (MAT) has been investigated as a therapeutic option for symptomatic COVID-19 patients in the outpatient setting at high-risk for progression to se...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Courtney, Lustberg, Mark, Sobhanie, Mohammad Mahdee, Lehman, Joy, Reed, Erica E, Kman, Nicholas E, Conroy, Mark, Dick, Michael, Allen, James N, Parsons, Jonathan, Malvestutto, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690747/
http://dx.doi.org/10.1093/ofid/ofab466.734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690747/
http://dx.doi.org/10.1093/ofid/ofab466.734

Ejemplares similares